Group 1 - Huakang Clean announced it is the first candidate for the bid of the Wuhan First Hospital expansion project with a bid amount of 54.88 million yuan and a construction period of 120 days [1] - Hualing Steel's subsidiary plans to invest 449.88 million yuan in a major overhaul project for its coking plant, aiming to address aging issues and restore production capacity over a 19-month construction period [2] - Yinjia Technology expects a net loss of 140 million to 110 million yuan for 2025, compared to a loss of 129 million yuan in the previous year [3] Group 2 - Guochuang High-tech forecasts a net profit of 16 million to 24 million yuan for 2025, recovering from a loss of 58.52 million yuan in the previous year [4] - Shiyi Da anticipates a net profit increase of 31 million to 46 million yuan for 2025, turning around from a loss of 23.41 million yuan last year [5] - Lijun Co. expects a net profit of 48 million to 66 million yuan for 2025, representing a decline of 45.05% to 60.03% compared to the previous year [7] Group 3 - Xindian Pharmaceutical plans to repurchase shares worth 25 million to 50 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 42 yuan per share [6] - Jingchen Co. has set the initial transfer price for its shares at 82.85 yuan per share, with a total of 13.1 million shares to be transferred to 28 institutional investors [8] - Zejing Pharmaceutical received approval for clinical trials of its innovative cancer immunotherapy drug ZG005 in combination with platinum-based chemotherapy for advanced nasopharyngeal and esophageal squamous cell carcinoma [9] Group 4 - Xingqi Eye Medicine expects a net profit of 662 million to 749 million yuan for 2025, marking a growth of 95.82% to 121.56% compared to the previous year [10] - Liancheng Precision anticipates a net loss of 12 million to 17 million yuan for 2025, reducing its loss from 37.96 million yuan in the previous year [11] - Beidou Star expects a net loss of 230 million to 290 million yuan for 2025, improving from a loss of 350 million yuan last year [13] Group 5 - Qing Shan Paper's affiliate won a bid for a wastewater treatment project worth 51.9 million yuan [15] - Yiling Pharmaceutical forecasts a net profit of 1.2 billion to 1.3 billion yuan for 2025, recovering from a loss of 725 million yuan in the previous year [16] - Huahai Pharmaceutical received a drug registration certificate for its product used in treating depression and obsessive-compulsive disorder [23] Group 6 - Nanjing Panda expects a net profit of 10 million to 15 million yuan for 2025, turning around from a loss of 189 million yuan last year [40] - Rui Sheng Intelligent anticipates a net profit of 33.92 million to 38.40 million yuan for 2025, representing a growth of 112% to 140% compared to the previous year [41] - Jiechang Drive expects a net profit of 395 million to 437 million yuan for 2025, with a growth of 40% to 55% compared to the previous year [43]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的马来酸氟伏沙明片的《药品注册证书》， 现将相关情况公告如下： 一、药品的基本情况 | 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 号 2026-004 | | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | 浙江华海药业股份有限公司 关于获得药品注册证书的公告 截至目前，公司在马来酸氟伏沙明片研发项目上已投入研发费用约人民币 439 万元。 药品名称：马来酸氟伏沙明片 剂型：片剂 规格：50mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 申请人：浙江华海药业股份有限公司 药品批准文号：国药准字 H20263094 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 马来 ...

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration of Fluoxetine Maleate Tablets, which are used to treat depression and obsessive-compulsive disorder [1] Group 1: Product Approval - The approval of Fluoxetine Maleate Tablets is classified as a Category 4 chemical drug, which is considered equivalent to passing the consistency evaluation according to national policies [1] - This product approval enhances the company's product line, contributing to increased market competitiveness [1]

Core Viewpoint - Huahai Pharmaceutical has received approval from the National Medical Products Administration for the registration of Fluvoxamine Maleate Tablets, which are indicated for the treatment of depression and obsessive-compulsive disorder [1] Group 1: Product Approval - The approved product is classified as a Class 4 chemical drug with a specification of 50mg [1] - The approval is seen as a significant step as it is equivalent to passing the consistency evaluation, which will enhance the company's product line and competitiveness [1] Group 2: Market Potential - According to the forecast from the China Insights Consultancy, the domestic market sales for this drug are expected to reach approximately 350 million yuan in the first half of 2025 [1] Group 3: Investment and Development - The company has invested around 4.39 million yuan in the research and development of this drug to date [1] Group 4: Market and Policy Risks - The production and sales of the approved product may be influenced by various factors, including policies and market conditions [1]

| | | 浙江华海药业股份有限公司 关于"华海转债"预计触发转股价格向下修正的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ●根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 规定，"上市公司应当在预计触发转股价格修正条件的 5 个交易日前及时披露提示 性公告。"自 2026 年 1 月 6 日至 2026 年 1 月 19 日，公司股票在连续 30 个交易日 中已有 10 个交易日的收盘价低于当期转股价格的 80%，预计触发转股价格向下修 正条件。若触发条件，公司将于触发条件当日召开董事会审议决定是否修正转股价 格，并及时履行信息披露义务。 一、可转债上市发行概况 根据中国证券监督管理委员会《关于核准浙江华海药业股份有限公司公开发行 可转换公司债券的批复》（证监许可[2020]2261 号），公司于 2020 年 11 月 2 日公 开发行了 1,842.60 万张可转换公司债券（以下简称"可转债"），每张面值 100.00 元，发行总额 184,260.00 万 ...

Core Viewpoint - Huahai Pharmaceutical's stock has experienced fluctuations, with a recent decline of 2.05% and a total market capitalization of 25.738 billion yuan. The company has seen a year-to-date stock price increase of 1.30%, but a decline of 4.92% over the last five trading days [1]. Financial Performance - For the period from January to September 2025, Huahai Pharmaceutical reported a revenue of 6.409 billion yuan, representing a year-on-year decrease of 11.57%. The net profit attributable to shareholders was 380 million yuan, down 63.12% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Huahai Pharmaceutical increased to 68,400, up by 1.58%. The average number of circulating shares per shareholder rose to 21,889 shares, an increase of 1.23% [2]. Dividend Distribution - Since its A-share listing, Huahai Pharmaceutical has distributed a total of 2.989 billion yuan in dividends. Over the past three years, the cumulative dividend payout has been 1.016 billion yuan [3]. Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders of Huahai Pharmaceutical include notable entities such as China Europe Medical Health Mixed A, which holds 28.785 million shares, a decrease of 4.4618 million shares from the previous period. Hong Kong Central Clearing Limited increased its holdings to 21.2462 million shares, up by 0.23487 million shares [3].

Group 1 - The core point of the news is that Huahai Pharmaceutical's stock has experienced a decline, with a 5.65% drop over the last three days, closing at 17.55 yuan per share on January 14, with a total market capitalization of 26.277 billion yuan [1] - Huahai Pharmaceutical, established on February 28, 2001, and listed on March 4, 2003, specializes in the research, production, and sales of various dosage forms of generic drugs, biological drugs, innovative drugs, and specialty raw materials [1] - The company's revenue composition includes finished drug sales at 61.86%, raw materials and intermediates sales at 36.75%, other sales at 0.78%, and technical services at 0.62% [1] Group 2 - From the perspective of major fund holdings, one fund under Qianhai United Fund holds Huahai Pharmaceutical as its eighth largest position, with 40,000 shares representing 3.38% of the fund's net value [2] - The fund, Qianhai United National Health Mixed A (003581), has incurred a floating loss of approximately 5,600 yuan today and a total floating loss of 42,000 yuan during the three-day decline [2] - The fund was established on December 29, 2016, with a latest scale of 15.6476 million yuan, and has achieved a year-to-date return of 9.78% [2]

Market Overview - The Shanghai Composite Index fell by 0.64% on January 13, with six industries experiencing gains, led by the oil and petrochemical sector (up 1.62%) and the pharmaceutical and biotechnology sector (up 1.21%) [1] - The defense and military industry and the electronics sector saw the largest declines, down 5.50% and 3.30% respectively [1] Capital Flow Analysis - The net outflow of capital from the two markets was 162.743 billion yuan, with only four industries seeing net inflows [1] - The pharmaceutical and biotechnology sector had the highest net inflow of capital at 4.348 billion yuan, followed by the oil and petrochemical sector with a net inflow of 586 million yuan [1] - The electronics industry experienced the largest net outflow, totaling 37.010 billion yuan, followed by the computer industry with a net outflow of 23.107 billion yuan [1] Pharmaceutical and Biotechnology Sector Performance - The pharmaceutical and biotechnology sector rose by 1.21%, with a total of 478 stocks in the sector, of which 329 stocks increased in value and 16 stocks hit the daily limit [2] - A total of 256 stocks in the sector saw net capital inflows, with 21 stocks receiving over 100 million yuan in net inflows; leading was Mindray Medical with a net inflow of 372 million yuan [2] - The stocks with the highest net outflows included Hainan Haiyao, Huahai Pharmaceutical, and Sanbo Brain Science, with net outflows of 204 million yuan, 164 million yuan, and 153 million yuan respectively [2] Top Gainers in Pharmaceutical Sector - Notable gainers included: - Mindray Medical: up 0.09% with a capital flow of 371.57 million yuan [3] - International Medical: up 9.96% with a capital flow of 290.33 million yuan [3] - Haiwang Biological: up 9.97% with a capital flow of 242.73 million yuan [3] - Boji Pharmaceutical: up 19.96% with a capital flow of 241.23 million yuan [3] - Erkang Pharmaceutical: up 19.95% with a capital flow of 237.43 million yuan [3] Top Losers in Pharmaceutical Sector - Notable losers included: - Hainan Haiyao: down 4.82% with a capital outflow of 203.78 million yuan [5] - Huahai Pharmaceutical: down 3.60% with a capital outflow of 163.67 million yuan [5] - Sanbo Brain Science: down 3.93% with a capital outflow of 153.22 million yuan [5] - Xiangrikui: down 5.49% with a capital outflow of 147.26 million yuan [5] - Luyan Pharmaceutical: down 3.74% with a capital outflow of 110.10 million yuan [5]

Core Viewpoint - The article discusses the initiation of a Phase III clinical trial for HB0025, a drug developed by Huahai Pharmaceutical's subsidiary, Huatai, aimed at treating advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy [1][4]. Group 1: Clinical Trial Details - The clinical trial, registered under CTR20260016, is a randomized, double-blind, multi-center study named DUALIGHT-02, which will evaluate the efficacy and safety of HB0025 in comparison to pembrolizumab combined with chemotherapy [2][4]. - The trial aims to enroll 480 participants in China, with the primary endpoint being progression-free survival (PFS) assessed by blinded independent central review (BICR) according to RECIST v1.1 criteria [4]. - The drug HB0025 is an innovative PD-L1/VEGF dual-specific fusion protein designed to target both tumor immune evasion pathways and tumor angiogenesis pathways, providing a dual mechanism of action [4]. Group 2: Drug Development Status - HB0025 has reached Phase III clinical trials in China, while it is currently in Phase II globally for various cancers, including hepatocellular carcinoma and triple-negative breast cancer [5][9]. - The drug has shown promising results in earlier trials, with an objective response rate (ORR) of 83.3% in the squamous NSCLC cohort and 100% in the high PD-L1 expressing group, along with a disease control rate (DCR) of 95.8% [7]. - Huahai Pharmaceutical has invested approximately 326 million yuan in the development of HB0025 [9].

Core Viewpoint - Huahai Pharmaceutical (600521.SH) has received approval from the National Medical Products Administration for the registration certificate of L-carnitine injection, which is used to treat complications arising from secondary carnitine deficiency in patients with chronic kidney failure undergoing long-term hemodialysis [1] Group 1 - The L-carnitine injection is indicated for symptoms such as cardiomyopathy, skeletal muscle disease, arrhythmia, hyperlipidemia, low blood pressure, and muscle cramps during dialysis [1] - The approval of L-carnitine injection enriches the company's product line and enhances its market competitiveness [1] - The product is classified as a Category 4 chemical drug, which is considered equivalent to passing the consistency evaluation according to national policies [1]